A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD

Chest

Volumn 148, Issue 2, 2015, Pages 397-407

  Rodrigo, Gustavo J ^a   Neffen, Hugo ^b  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b 'O Alassia' Children's Hospital   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG COMBINATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANDROSTADIENES; BENZYL ALCOHOLS; CHLOROBENZENES; DRUG COMBINATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84939231892     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0084     Document Type: Article

References (30)

1. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013; 7: 1201-1208.
2. Rodrigo GJ, Plaza V, Castro-Rodrguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012; 25 (1): 40-47.
3. Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest. 2014; 146 (2): 309-317.
4. Rodrigo GJ, Plaza V. Efficacy and safety of indacaterol and glycopyrronium in COPD: an update. Chest. 2014; 146(2): e75.
5. Global initiative for the diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. http://www.goldcopd.com/uploads/users/files/GOLD-Report-2014-Oct30.pdf. Updated 2014. Accessed December 15, 2014.
6. Celli B, Crater G, Kilbride S, et al. Oncedaily umeclidinium/vilanterol 125/25 mcg therapy in COPD: a randomized, controlled study. Chest. 2014; 145 (5): 981-991.
7. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2 (6): 472-486.
8. Liberati A, Altman DG, TetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151 (4): W65-W94.
9. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23 (6): 932-946.
10. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991; 85 (suppl B): 25-31.
11. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. C hest. 1984; 85 (6): 751-758.
12. Clinical safety data management: definitions and standards for expedited reporting. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) website. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E2A/Step4/E2A-Guideline.pdf. Accessed December 11, 2014.
13. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414): 557-560.
15. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to Meta-analysis. Chichester, England: John Wiley and Sons, Ltd; 2009.
16. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity, combining results from several studies in meta-analysis. In: Egger M, Smith Altman DG, eds. S ystematic Reviews in Health Care: Meta-analysis in Context. London, England: BMJ; 2001: 285-312.
17. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107 (10): 1538-1546.
18. Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. R espir Res. 2014; 15: 78.
19. GSK. An exercise endurance study to evaluate the effects of treatment of chronic obstructive pulmonary disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study B. Protocol ID 114418 (NCT01323660). GSK Clinical Study Register. http://www.gsk-clinicalstudyregister.com/study/114418?study-ids5114418#rs. Accessed December 10, 2014.
20. GSK. An exercise endurance study to evaluate the effects of treatment of chronic obstructive pulmonary disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A. Protocol ID 114417 (NCT01328444). GSK Clinical Study Register. http://www.gsk-clinicalstudyregister.com/study/114417?study-ids 5 114417#rs. Accessed December 10, 2014.
21. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014; 108 (12): 1752-1760.
22. GSK. An exercise endurance study to evaluate the effects of treatment of chronic obstructive pulmonary disease (COPD) patients with a dual bronchodilator: GSK573719/GW642444. Study A. Protocol ID 114930 (NCT01817764). GSK Clinical Study Register. http://www.gsk-clinicalstudyregister.com/study/114930?study-ids 5 114930#rs. Accessed December 10, 2014.
23. GSK. A randomized, multi-center, doubleblind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium bromide/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD. Protocol ID 116134 (NCT01822899). GSK Clinical Study Register. http://www.gsk-clinicalstudyregister.com/study/116134?study-ids 5 116134#rs. Accessed December 10, 2014.
24. GSK. A randomized, multi-center, doubleblind, double-dummy, parallel group study to evaluate the efficacy umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD. Protocol ID 114951 (NCT01879410). GSK Clinical Study Register. http://www.gsk-clinicalstudy register.com/study/114951?study-ids 5 114951#rs. Accessed December 10, 2014.
25. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014; 189 (3): 250-255.
26. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease. US Food and Drug Administration website. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm. December 18, 2013. Accessed December 8, 2014.
27. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31 (2): 416-469.
28. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005; 2 (1): 111-124.
29. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009; 64 (11): 939-943.
30. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011; 105 (3): 435-441.